SAN FRANCISCO — After three decades working on cell and gene therapy, David DiGiusto has expertise that’s hard to find. So hard to find, in fact, that one cancer immunotherapy company stopped at nothing to try to hire him.

First, DiGiusto was told he could name his salary. Next, he was told he could name his desired equity stake. When those offers didn’t work, the chairman of the board tried to woo DiGiusto with a last-ditch deal: He’d buy DiGiusto a $10,000 Omega Speedmaster wristwatch — if only he’d join the company.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

  • And yet,
    cross referencing his linkedin profile with his pubmed record, it seems he went through both his MS and PhD without publishing one single first author research article (from where I come from, that wouldn’t qualify you for a PhD). And, although, being research professor (how that happened?) at City of Hope institute since 1998, he didn’t publish a single research article (just a few reviews) till 2006! That’s 8 years without delivering any actual new research!
    I wish academic institutions, biotechs, karma and the universe were as much understanding and entrusting me, as they were with him!

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy